

Renzo Colombo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10198488/publications.pdf>

Version: 2024-02-01

199
papers

8,699
citations

38660

50
h-index

53109

85
g-index

209
all docs

209
docs citations

209
times ranked

6742
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3353-3360.	0.8	474
2	Holmium Laser Enucleation of the Prostate Versus Open Prostatectomy for Prostates >70g: 24-Month Follow-up. <i>European Urology</i> , 2006, 50, 563-568.	0.9	331
3	Sexual Dysfunction is Common in Women with Lower Urinary Tract Symptoms and Urinary Incontinence: Results of a Cross-Sectional Study. <i>European Urology</i> , 2004, 45, 642-648.	0.9	316
4	Multicentric Study Comparing Intravesical Chemotherapy Alone and With Local Microwave Hyperthermia for Prophylaxis of Recurrence of Superficial Transitional Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 4270-4276.	0.8	244
5	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. <i>European Urology</i> , 2020, 77, 439-446.	0.9	228
6	Long-term Outcomes of Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer: Results of a Single-institution Series with a Minimum Follow-up of 5 Years. <i>European Urology</i> , 2015, 67, 299-309.	0.9	211
7	Pelvic/Retroperitoneal Salvage Lymph Node Dissection for Patients Treated With Radical Prostatectomy With Biochemical Recurrence and Nodal Recurrence Detected by [11C]Choline Positron Emission Tomography/Computed Tomography. <i>European Urology</i> , 2011, 60, 935-943.	0.9	209
8	Prevention and Management of Complications Following Radical Cystectomy for Bladder Cancer. <i>European Urology</i> , 2010, 57, 983-1001.	0.9	194
9	Prognostic Factors and Risk Groups in T1G3 Non-muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients. <i>European Urology</i> , 2015, 67, 74-82.	0.9	190
10	Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). <i>BJU International</i> , 2011, 107, 912-918.	1.3	169
11	The Role of a Combined Regimen With Intravesical Chemotherapy and Hyperthermia in the Management of Non-muscle-invasive Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2011, 60, 81-93.	0.9	166
12	A Prospective Study Comparing Paroxetine Alone Versus Paroxetine Plus Sildenafil in Patients With Premature Ejaculation. <i>Journal of Urology</i> , 2002, 168, 2486-2489.	0.2	160
13	Preliminary European Results of Local Microwave Hyperthermia and Chemotherapy Treatment in Intermediate or High Risk Superficial Transitional Cell Carcinoma of the Bladder. <i>European Urology</i> , 2004, 46, 65-72.	0.9	144
14	LAPAROSCOPIC CROSS-TRIGONAL COHEN URETERONEOCYSTOSTOMY: NOVEL TECHNIQUE. <i>Journal of Urology</i> , 2001, 166, 1811-1814.	0.2	143
15	Are Infertile Men Less Healthy than Fertile Men? Results of a Prospective Case-Control Survey. <i>European Urology</i> , 2009, 56, 1025-1032.	0.9	141
16	Prognostic Value of Lymph Node Dissection in Patients with Muscle-Invasive Transitional Cell Carcinoma of the Upper Urinary Tract. <i>European Urology</i> , 2008, 53, 794-802.	0.9	137
17	Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020, 77, 701-710.	0.9	128
18	Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. <i>BJU International</i> , 2006, 98, 329-334.	1.3	126

#	ARTICLE	IF	CITATIONS
19	Performance Characteristics of Computed Tomography in Detecting Lymph Node Metastases in Contemporary Patients with Prostate Cancer Treated with Extended Pelvic Lymph Node Dissection. <i>European Urology</i> , 2012, 61, 1132-1138.	0.9	120
20	The impact of reâ€transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 highâ€grade/Grade 3 bladder cancer treated with bacille Calmetteâ€GuÃ©rin. <i>BJU International</i> , 2016, 118, 44-52.	1.3	110
21	Combined Thermo-Chemotherapy for Recurrent Bladder Cancer After Bacillus Calmette-Guerin. <i>Journal of Urology</i> , 2009, 182, 1313-1317.	0.2	109
22	Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. <i>Urology</i> , 2004, 63, 466-471.	0.5	104
23	Radical Prostatectomy After Previous Prostate Surgery: Clinical and Functional Outcomes. <i>Journal of Urology</i> , 2006, 176, 2459-2463.	0.2	104
24	Predicting Erectile Function Recovery after Bilateral Nerve Sparing Radical Prostatectomy: A Proposal of a Novel Preoperative Risk Stratification. <i>Journal of Sexual Medicine</i> , 2010, 7, 2521-2531.	0.3	102
25	Overall Clinical Outcomes After Nerve and Seminal Sparing Radical Cystectomy for the Treatment of Organ Confined Bladder Cancer. <i>Journal of Urology</i> , 2004, 171, 1819-1822.	0.2	89
26	Neoadjuvant Combined Microwave Induced Local Hyperthermia and Topical Chemotherapy Versus Chemotherapy Alone for Superficial Bladder Cancer. <i>Journal of Urology</i> , 1996, 155, 1227-1232.	0.2	87
27	Diagnosis and Treatment of Bladder Endometriosis: State of the Art. <i>Urologia Internationalis</i> , 2012, 89, 249-258.	0.6	85
28	Ureteral Endometriosis: Proposal for a Diagnostic and Therapeutic Algorithm with a Review of the Literature. <i>Urologia Internationalis</i> , 2013, 91, 1-9.	0.6	78
29	NERVE AND SEMINAL SPARING RADICAL CYSTECTOMY WITH ORTHOTOPIC URINARY DIVERSION FOR SELECT PATIENTS WITH SUPERFICIAL BLADDER CANCER: AN INNOVATIVE SURGICAL APPROACH. <i>Journal of Urology</i> , 2001, 165, 51-55.	0.2	75
30	Prediction of Functional Outcomes After Nerve-Sparing Radical Prostatectomy: Results of Conditional Survival Analyses. <i>European Urology</i> , 2012, 62, 42-52.	0.9	75
31	Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. <i>European Urology</i> , 2020, 77, 636-643.	0.9	75
32	Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 273-278.	1.1	73
33	Holmium Laser Enucleation Versus Transurethral Resection of the Prostate. Are Histological Findings Comparable?. <i>Journal of Urology</i> , 2004, 171, 1203-1206.	0.2	73
34	Leydig cell tumour of the testis: presentation, therapy, longâ€term followâ€up and the role of organâ€sparing surgery in a singleâ€institution experience. <i>BJU International</i> , 2009, 103, 197-200.	1.3	72
35	Thermo–Chemotherapy and Electromotive Drug Administration of Mitomycin C in Superficial Bladder Cancer Eradication. <i>European Urology</i> , 2001, 39, 95-100.	0.9	70
36	Conservative Surgical Therapy for Leydig Cell Tumor. <i>Journal of Urology</i> , 2007, 178, 507-511.	0.2	69

#	ARTICLE	IF	CITATIONS
37	Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. <i>BJU International</i> , 2016, 117, 604-610.	1.3	68
38	Original Articles: Bladder Cancer: A New Approach Using Local Combined Microwave Hyperthermia and Chemotherapy in Superficial Transitional Bladder Carcinoma Treatment. <i>Journal of Urology</i> , 1995, 153, 959-963.	0.2	67
39	Vestibular Flap Urethroplasty for Strictures of the Female Urethra. <i>Urologia Internationalis</i> , 2002, 69, 12-16.	0.6	67
40	Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 335-341.	0.8	66
41	Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study†. <i>Annals of Oncology</i> , 2020, 31, 1755-1763.	0.6	65
42	Serum Sex Steroids Depict a Nonlinear U-Shaped Association with High-Risk Prostate Cancer at Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2012, 18, 3648-3657.	3.2	62
43	Lymphadenectomy for Bladder Cancer at the Time of Radical Cystectomy. <i>European Urology</i> , 2013, 64, 266-276.	0.9	62
44	Radical Prostatectomy for Incidental (Stage T1a–T1b) Prostate Cancer: Analysis of Predictors for Residual Disease and Biochemical Recurrence. <i>European Urology</i> , 2008, 54, 118-125.	0.9	61
45	Impact of Surgical Volume on the Rate of Lymph Node Metastases in Patients Undergoing Radical Prostatectomy and Extended Pelvic Lymph Node Dissection for Clinically Localized Prostate Cancer. <i>European Urology</i> , 2008, 54, 794-804.	0.9	61
46	Monofocal and plurifocal high-grade prostatic intraepithelial neoplasia on extended prostate biopsies: factors predicting cancer detection on extended repeat biopsy. <i>Urology</i> , 2004, 63, 1105-1110.	0.5	56
47	Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial. <i>European Urology</i> , 2020, 77, 576-580.	0.9	55
48	Transrectal Microwave Hyperthermia for Benign Prostatic Hyperplasia: Long-Term Clinical, Pathological and Ultrastructural Patterns. <i>Journal of Urology</i> , 1992, 148, 321-325.	0.2	53
49	Ileal Conduit as the Standard for Urinary Diversion After Radical Cystectomy for Bladder Cancer. <i>European Urology Supplements</i> , 2010, 9, 736-744.	0.1	53
50	The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 484.e19-484.e25.	0.8	53
51	General versus spinal anesthesia in patients undergoing radical retropubic prostatectomy: results of a prospective, randomized study. <i>Urology</i> , 2004, 64, 95-100.	0.5	52
52	A Critical Analysis of Orthotopic Bladder Substitutes in Adult Patients with Bladder Cancer: Is There a Perfect Solution?. <i>European Urology</i> , 2010, 58, 374-383.	0.9	52
53	Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: A 20-year single center experience. <i>European Journal of Surgical Oncology</i> , 2016, 42, 735-743.	0.5	49
54	Dynamic Gadolinium-Enhanced Magnetic Resonance Imaging in Staging of Superficial Bladder Cancer. <i>Journal of Urology</i> , 1996, 155, 1594-1599.	0.2	48

#	ARTICLE	IF	CITATIONS
55	LOCAL MICROWAVE HYPERTHERMIA AND INTRAVESICAL CHEMOTHERAPY AS BLADDER SPARING TREATMENT FOR SELECT MULTIFOCAL AND UNRESECTABLE SUPERFICIAL BLADDER TUMORS. <i>Journal of Urology</i> , 1998, 159, 783-787.	0.2	48
56	Effects of Short-Term Treatment with the $\hat{\pm}$ (1)-Blocker Alfuzosin on Urodynamic Pressure/Flow Parameters in Patients with Benign Prostatic Hyperplasia. <i>European Urology</i> , 1997, 32, 47-53.	0.9	47
57	Renal Sinus Fat Invasion in pT3a Clear Cell Renal Cell Carcinoma Affects Outcomes of Patients Without Nodal Involvement or Distant Metastases. <i>Journal of Urology</i> , 2009, 181, 2027-2032.	0.2	47
58	Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. <i>Cancer</i> , 2011, 117, 3953-3962.	2.0	47
59	Long-Term Follow-Up Using Testicle-Sparing Surgery for Leydig Cell Tumor. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 321-324.	0.9	45
60	Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 259-264.	0.8	44
61	Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 674-683.	0.4	42
62	Concordance and Clinical Significance of Uncommon Variants of Bladder Urothelial Carcinoma in Transurethral Resection and Radical Cystectomy Specimens. <i>Urology</i> , 2014, 84, 1141-1146.	0.5	42
63	RECONFIGURATION OF THE SEVERELY FIBROTIC PENIS WITH A PENILE IMPLANT. <i>Journal of Urology</i> , 2001, 166, 1782-1786.	0.2	41
64	Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non-muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study. <i>European Urology</i> , 2012, 62, 797-802.	0.9	41
65	Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-naïve Urothelial Bladder Cancer Patients. <i>European Urology Oncology</i> , 2020, 3, 784-788.	2.6	41
66	Combined Intravesical Chemotherapy with Mitomycin C and Local Bladder Microwave-Induced Hyperthermia as a Preoperative Therapy for Superficial Bladder Tumors. <i>European Urology</i> , 1991, 20, 204-210.	0.9	40
67	Impact of Venous Tumour Thrombus Consistency (Solid vs Friable) on Cancer-specific Survival in Patients with Renal Cell Carcinoma. <i>European Urology</i> , 2011, 60, 358-365.	0.9	39
68	What Is the Definition of a Satisfactory Erectile Function After Bilateral Nerve Sparing Radical Prostatectomy?. <i>Journal of Sexual Medicine</i> , 2011, 8, 1210-1217.	0.3	38
69	Effect of Allogeneic Intraoperative Blood Transfusion on Survival in Patients Treated With Radical Cystectomy for Nonmetastatic Bladder Cancer: Results From a Single High-Volume Institution. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 562-567.	0.9	37
70	Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical experience. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 47, 127-139.	2.0	36
71	Nerve-Sparing Radical Retropubic Prostatectomy in Patients Previously Submitted to Holmium Laser Enucleation of the Prostate for Bladder Outlet Obstruction Due to Benign Prostatic Enlargement. <i>European Urology</i> , 2008, 53, 1180-1185.	0.9	35
72	Clinical Reliability of the 2004 WHO Histological Classification System Compared With the 1973 WHO System for Ta Primary Bladder Tumors. <i>Journal of Urology</i> , 2011, 186, 2194-2200.	0.2	35

#	ARTICLE	IF	CITATIONS
73	Preoperative Erectile Function Represents a Significant Predictor of Postoperative Urinary Continence Recovery in Patients Treated With Bilateral Nerve Sparing Radical Prostatectomy. <i>Journal of Urology</i> , 2012, 187, 569-574.	0.2	35
74	Choosing the Best Candidates for Penile Rehabilitation After Bilateral Nerve-Sparing Radical Prostatectomy. <i>Journal of Sexual Medicine</i> , 2012, 9, 608-617.	0.3	35
75	Fifteen-year single-centre experience with three different surgical procedures of nerve-sparing cystectomy in selected organ-confined bladder cancer patients. <i>World Journal of Urology</i> , 2015, 33, 1389-1395.	1.2	34
76	Laparoscopic Nerve- and Seminal-Sparing Cystectomy with Orthotopic Ileal Neobladder: The First Three Cases. <i>European Urology</i> , 2003, 44, 567-572.	0.9	33
77	Impact of the introduction of a robotic training programme on prostate cancer stage migration at a single tertiary referral centre. <i>BJU International</i> , 2013, 111, 1222-1230.	1.3	33
78	Usefulness of pT1 substaging in papillary urothelial bladder carcinoma. <i>Diagnostic Pathology</i> , 2016, 11, 6.	0.9	33
79	Perioperative and Oncologic Outcomes of Nephrectomy and Caval Thrombectomy Using Extracorporeal Circulation and Deep Hypothermic Circulatory Arrest for Renal Cell Carcinoma Invading the Supradiaphragmatic Inferior Vena Cava and/or Right Atrium. <i>European Urology</i> , 2018, 73, 793-799.	0.9	33
80	Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma. <i>Anticancer Research</i> , 2014, 34, 3225-30.	0.5	33
81	Transrectal Microwave Hyperthermia for Advanced Prostate Cancer: Long-Term Clinical Results. <i>Journal of Urology</i> , 1992, 148, 342-345.	0.2	31
82	Feasibility and Clinical Roles of Different Substaging Systems at First and Second Transurethral Resection in Patients with T1 High-Grade Bladder Cancer. <i>European Urology Focus</i> , 2018, 4, 87-93.	1.6	31
83	Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 48-53.	3.0	30
84	Histological and Ultrastructural Evaluation of Extracorporeal Shock Wave Lithotripsy-Induced Acute Renal Lesions: Preliminary Report. <i>European Urology</i> , 1989, 16, 207-211.	0.9	29
85	Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. <i>World Journal of Urology</i> , 2018, 36, 1621-1627.	1.2	29
86	Secondary scrotal lymphedema: A novel microsurgical approach. <i>Microsurgery</i> , 2007, 27, 655-656.	0.6	28
87	Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer. <i>International Journal of Hyperthermia</i> , 2016, 32, 351-362.	1.1	28
88	Bladder cancer cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of sphingolipids metabolism. <i>Scientific Reports</i> , 2017, 7, 42157.	1.6	28
89	Are Referral Centers for Non-Muscle-Invasive Bladder Cancer Compliant to EAU Guidelines? A Report from the Vesical Antiblasic Therapy Italian Study. <i>Urologia Internationalis</i> , 2011, 86, 19-24.	0.6	27
90	Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e603-e607.	0.9	27

#	ARTICLE	IF	CITATIONS
91	Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 77.e1-77.e7.	0.8	26
92	Counselling the patient with prostate cancer about treatment-related erectile dysfunction. <i>Current Opinion in Urology</i> , 2001, 11, 611-617.	0.9	25
93	Clinical Lymphadenopathy in Urothelial Cancer: A Transatlantic Collaboration on Performance of Cross-sectional Imaging and Oncologic Outcomes in Patients Treated with Radical Cystectomy Without Neoadjuvant Chemotherapy. <i>European Urology Focus</i> , 2018, 4, 245-251.	1.6	24
94	Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?. <i>European Urology</i> , 2021, 80, 319-322.	0.9	24
95	Plasma mitomycin C concentrations determined by HPLC coupled to solid-phase extraction. <i>Clinical Chemistry</i> , 1997, 43, 615-618.	1.5	23
96	Oncological predictive value of the 2004 World Health Organisation grading classification in primary <sc>T1</sc> non-muscle-invasive bladder cancer. A step forward or back?. <i>BJU International</i> , 2015, 115, 267-273.	1.3	23
97	Detubularized Sigmoid Colon For Bladder Replacement After Radical Cystectomy. <i>Journal of Urology</i> , 1994, 152, 1409-1412.	0.2	22
98	General versus spinal anesthesia with different forms of sedation in patients undergoing radical retropubic prostatectomy: Results of a prospective, randomized study. <i>International Journal of Urology</i> , 2006, 13, 1185-1190.	0.5	22
99	Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials?. <i>Urologia Internationalis</i> , 2016, 96, 20-24.	0.6	22
100	Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. <i>World Journal of Urology</i> , 2020, 38, 1959-1968.	1.2	22
101	Primary and Pure Neuroendocrine Tumor of the Prostate. <i>European Urology</i> , 2004, 45, 166-170.	0.9	21
102	Effect of Ethanol and Red Wine on Ochratoxin A-Induced Experimental Acute Nephrotoxicity. <i>Journal of Agricultural and Food Chemistry</i> , 2005, 53, 6924-6929.	2.4	21
103	The Impact of Perioperative Blood Transfusion on Survival of Bladder Cancer Patients Submitted to Radical Cystectomy: Role of Anemia Status. <i>European Urology Focus</i> , 2016, 2, 86-91.	1.6	20
104	Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 256.e7-256.e13.	0.8	20
105	The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2021, 4, 829-833.	2.6	20
106	Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy. <i>World Journal of Urology</i> , 2015, 33, 1419-1428.	1.2	19
107	Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy. <i>World Journal of Urology</i> , 2018, 36, 639-644.	1.2	18
108	Postoperative Orgasmic Function Increases over Time in Patients Undergoing Nerve-Sparing Radical Prostatectomy. <i>Journal of Sexual Medicine</i> , 2010, 7, 149-155.	0.3	17

#	ARTICLE	IF	CITATIONS
109	Extended Pelvic Lymph Node Dissection Does Not Affect Erectile Function Recovery in Patients Treated with Bilateral Nerve-sparing Radical Prostatectomy. <i>Journal of Sexual Medicine</i> , 2012, 9, 2187-2194.	0.3	17
110	Detrusor Muscle in TUR-Derived Bladder Tumor Specimens: Can We Actually Improve the Surgical Quality?. <i>Journal of Endourology</i> , 2016, 30, 400-405.	1.1	17
111	Morphodynamic and biochemical assessment of seminal plasma in patients who underwent local prostatic hyperthermia. <i>Prostate</i> , 1990, 16, 325-330.	1.2	16
112	A reappraisal of the role of vesicourethral anastomosis biopsy in patient candidates for salvage radiation therapy after radical prostatectomy. <i>Radiotherapy and Oncology</i> , 2007, 82, 30-37.	0.3	16
113	A novel tool to assess the risk of urinary incontinence after nerve-sparing radical prostatectomy. <i>BJU International</i> , 2013, 111, 905-913.	1.3	16
114	Effect on postoperative survival of the status of distal ureteral margin: The necessity to achieve negative margins at the time of radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 59.e15-59.e22.	0.8	16
115	Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 307.e9-307.e14.	0.8	16
116	Multimodal Therapy for Stones in Pelvic Kidneys. <i>Urologia Internationalis</i> , 1991, 46, 29-34.	0.6	15
117	Update of the minimally invasive therapies for benign prostatic hyperplasia. <i>Current Opinion in Urology</i> , 2005, 15, 49-53.	0.9	15
118	Pfannenstiel versus Vertical Laparotomy in Patients Undergoing Radical Retropubic Prostatectomy with Spinal Anesthesia: Results of a Prospective, Randomized Trial. <i>European Urology</i> , 2005, 47, 202-208.	0.9	15
119	Is Sperm Banking of Interest to Patients With Nongerm Cell Urological Cancer Before Potentially Fertility Damaging Treatments?. <i>Journal of Urology</i> , 2009, 182, 1101-1107.	0.2	15
120	Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy. <i>World Journal of Urology</i> , 2018, 36, 1775-1781.	1.2	15
121	Long Term Experience with the Prostatic Spiral for Urinary Retention due to Benign Prostatic Hyperplasia. <i>Scandinavian Journal of Urology and Nephrology</i> , 1991, 25, 21-24.	1.4	14
122	A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinium-based chemotherapy. <i>World Journal of Urology</i> , 2016, 34, 207-213.	1.2	14
123	Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 528.e1-528.e5.	0.8	14
124	Hospital care in Departments defined as COVID-free: A proposal for a safe hospitalization protecting healthcare professionals and patients not affected by COVID-19. <i>Archivio Italiano Di Urologia Andrologia</i> , 2020, 92, .	0.4	14
125	The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 151.e17-151.e23.	0.8	13
126	There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. Implications for focal therapies. <i>Prostate</i> , 2012, 72, 925-930.	1.2	12

#	ARTICLE	IF	CITATIONS
127	Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: Overview and the Unmet Clinical Need for Alternative Adjuvant Therapy as Studied in the MAGNOLIA Trial. <i>European Urology</i> , 2014, 65, 509-511.	0.9	12
128	Pembrolizumab as Neoadjuvant Therapy Preceding Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Group, Phase 2 Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	12
129	Radical Nephrocapsulectomy and Caval Thrombectomy with Extracorporeal Circulation and Deep Hypothermic Circulatory Arrest in Right Anterior Minithoracotomy: A Minimally Invasive Approach. <i>Urology</i> , 2008, 71, 957-961.	0.5	11
130	Editorial Comment on: Defining Early Morbidity of Radical Cystectomy for Patients with Bladder Cancer Using a Standardized Reporting Methodology. <i>European Urology</i> , 2009, 55, 175-176.	0.9	11
131	Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy. <i>BJU International</i> , 2011, 107, 1243-1249.	1.3	11
132	Preoperative Favorable Characteristics in Bladder Cancer Patients Cannot Substitute the Necessity of Extended Lymphadenectomy During Radical Cystectomy: A Sensitivity Curve Analysis. <i>Urology</i> , 2016, 88, 97-103.	0.5	11
133	Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration. <i>European Urology Focus</i> , 2022, 8, 1270-1277.	1.6	11
134	Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy. <i>Journal of Urology</i> , 2021, 206, 885-893.	0.2	11
135	Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors. <i>European Urology Oncology</i> , 2022, 5, 30-41.	2.6	11
136	Incidence and Predictors of 30-Day Readmission in Patients Treated With Radical Cystectomy: A Single Center European Experience. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e341-e346.	0.9	10
137	Unsuccessful Investigation of Preoperative Sexual Health Issues in the Prostate Cancer Couple: Results of a Real-Life Psychometric Survey at a Major Tertiary Academic Center. <i>Journal of Sexual Medicine</i> , 2009, 6, 3347-3355.	0.3	9
138	Urinary Bladder Preservation for Muscle-invasive Bladder Cancer: A Survey among Radiation Oncologists of Lombardy, Italy. <i>Tumori</i> , 2015, 101, 174-178.	0.6	9
139	Impact of Intra- and Postoperative Blood Transfusion on the Incidence, Timing, and Pattern of Disease Recurrence After Radical Cystectomy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e681-e688.	0.9	9
140	Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification?. <i>Urologia Internationalis</i> , 2019, 102, 269-276.	0.6	9
141	Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 7-14.e3.	0.9	9
142	Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 3337-3344.	1.2	9
143	Urological complications after simultaneous renal and pancreatic transplantation. <i>The European Journal of Surgery</i> , 2002, 168, 609-613.	1.0	9
144	Photodynamic diagnosis for follow-up of carcinoma in situ of the bladder. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 1003-7.	0.9	9

#	ARTICLE	IF	CITATIONS
145	Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration. <i>World Journal of Urology</i> , 2022, 40, 1167-1174.	1.2	9
146	Transrectal Hyperthermia-Induced Histological and Ultrastructural Changes of Human Benign Prostatic Hyperplasia Tissue. <i>European Urology</i> , 1992, 22, 74-78.	0.9	8
147	Imaging of Renal Cell Carcinoma with Gadolinium-Enhanced Magnetic Resonance: Radiological and Pathological Study. <i>Urologia Internationalis</i> , 1995, 54, 121-127.	0.6	8
148	A critical analysis of laser prostatectomy in the management of benign prostatic hyperplasia. <i>BJU International</i> , 2005, 96, 736-739.	1.3	8
149	Impact of Prostate Involvement on Outcomes in Patients Treated with Radical Cystoprostatectomy for Bladder Cancer. <i>Urologia Internationalis</i> , 2017, 98, 290-297.	0.6	8
150	The surgical management of patients with clinical stage T4 bladder cancer: A single institution experience. <i>European Journal of Surgical Oncology</i> , 2017, 43, 808-814.	0.5	8
151	Multicentre International Study for the Prevention with iAluRil of Radio-induced Cystitis (MISTIC): A Randomised Controlled Study. <i>European Urology Open Science</i> , 2021, 26, 45-54.	0.2	8
152	Can Gemcitabine Instillation Ablate Solitary Low-Risk Non-Muscle-Invasive Bladder Cancer? Results of a Phase II Marker Lesion Study. <i>Urologia Internationalis</i> , 2011, 87, 470-474.	0.6	7
153	Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e245-e250.	0.9	7
154	Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer. <i>European Urology Focus</i> , 2021, 7, 1067-1074.	1.6	7
155	Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent. <i>World Journal of Urology</i> , 2021, 39, 1947-1953.	1.2	7
156	Protocol of the Italian Radical Cystectomy Registry (RIC): a non-randomized, 24-month, multicenter study comparing robotic-assisted, laparoscopic, and open surgery for radical cystectomy in bladder cancer. <i>BMC Cancer</i> , 2021, 21, 51.	1.1	7
157	Bladder perforation during transurethral resection of the bladder: a comprehensive algorithm for diagnosis, management and follow-up. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	1.3	7
158	Combined treatment with local thermo-chemotherapy for non muscle invasive bladder cancer. The present role in the light of acquired data and preliminary cumulative clinical experiences. <i>Archivio Italiano Di Urologia Andrologia</i> , 2008, 80, 149-56.	0.4	7
159	Local Bacillus Calmette-Guerin Therapy for Superficial Bladder Cancer: Clinical, Histological and Ultrastructural Patterns. <i>Scandinavian Journal of Urology and Nephrology</i> , 1990, 24, 191-198.	1.4	6
160	An original balloon-expanding urethral suture guide for radical prostatectomy. <i>Urology</i> , 1995, 46, 562-564.	0.5	6
161	Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy. <i>World Journal of Urology</i> , 2012, 30, 533-539.	1.2	6
162	Radiofrequency-Induced Thermo-Chemotherapy Effect (Rite) for Non Muscle Invasive Bladder Cancer Treatment: Current Role and Perspectives. <i>Urologia</i> , 2016, 83, 7-17.	0.3	6

#	ARTICLE	IF	CITATIONS
163	The Clinical Value of PSA Increase during Intravesical Adjuvant Therapy for Nonmuscle-Invasive Bladder Cancer. <i>Urologia</i> , 2016, 83, 145-148.	0.3	6
164	The impact of completeness of last transurethral resection of bladder tumors on the outcomes of radical cystectomy. <i>World Journal of Urology</i> , 2019, 37, 2707-2714.	1.2	6
165	Evaluation of Cause of Death After Radical Cystectomy for Patients With Bladder Cancer: The Impact of Age at the Time of Surgery. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e541-e548.	0.9	6
166	Effect of Stage Migration on Bladder Cancer: A Slow but Steady Improvement in Long-Term Survival Rates After Radical Cystectomy in Previous 25 Years. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e223-e228.	0.9	5
167	Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology "Young Academic Urologists. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 195.e27-195.e35.	0.8	5
168	Transrectal Prostatic Hyperthermia and Urinary Retention Secondary to Benign Prostatic Hyperplasia: A 2-Year Follow-Up Study. <i>Journal of Endourology</i> , 1992, 6, 261-264.	1.1	4
169	The Clinical Use of Statistical Permutation Test Methodology: A Tool for Identifying Predictive Variables of Outcome. <i>Urologia Internationalis</i> , 2015, 94, 262-269.	0.6	4
170	Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 672.e1-672.e6.	0.8	4
171	Quality-of-Life Outcomes in Female Patients With Ileal Conduit or Orthotopic Neobladder Urinary Diversion: 6-Month Results of a Multicenter Prospective Study. <i>Frontiers in Oncology</i> , 2022, 12, 855546.	1.3	4
172	How to improve patient selection for neoadjuvant chemotherapy in bladder cancer patients candidate for radical cystectomy and pelvic lymph node dissection. <i>World Journal of Urology</i> , 2020, 38, 1229-1233.	1.2	3
173	Perioperative and oncologic outcomes of open radical nephrectomy and inferior vena cava thrombectomy with liver mobilization and Pringle maneuver for Mayo III level tumor thrombus: single institution experience. <i>Minerva Urology and Nephrology</i> , 2020, , .	1.3	3
174	The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy. <i>Clinical Genitourinary Cancer</i> , 2021, , .	0.9	3
175	Herniation of the amniotic sac into the bladder through a vesico-uterine fistula in the 32nd week of pregnancy. <i>British Journal of Obstetrics and Gynaecology</i> , 2001, 108, 1300-1301.	0.9	2
176	Adjuvant recMAGE-A3 Immunotherapy After Cystectomy for Muscle-invasive Bladder Cancer: Lessons Learned from the Phase 2 MAGNOLIA Clinical Trial. <i>European Urology Focus</i> , 2019, 5, 849-852.	1.6	2
177	Prevention and management of complications following radical cystectomy for bladder cancer. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2010, 36, 642-643.	0.7	2
178	Perioperative and oncologic outcomes of open radical nephrectomy and inferior vena cava thrombectomy with liver mobilization and Pringle maneuver for Mayo III level tumor thrombus: single institution experience. <i>Minerva Urology and Nephrology</i> , 2022, 73, .	1.3	2
179	Herniation of the amniotic sac into the bladder through a vesico-uterine fistula in the 32nd week of pregnancy. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2001, 108, 1300-1301.	1.1	1
180	Re: Lymphatic Invasion is a Prognostic Factor for Bladder Cancer Treated with Radical Cystectomy. <i>European Urology</i> , 2007, 52, 1797-1798.	0.9	1

#	ARTICLE	IF	CITATIONS
181	Re: Long-Term Outcomes of a Randomized Controlled Trial Comparing Thermochemotherapy With Mitomycin-C Alone as Adjuvant Treatment for Non-Muscle-Invasive Bladder Cancer (NMIBC). <i>Journal of Urology</i> , 2011, 186, 1808-1809.	0.2	1
182	PECULIAR: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscle-invasive urothelial bladder cancer (MIUBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4595-TPS4595.	0.8	1
183	Pathologic features and clinical outcome after anatomic radical prostatectomy by transcoccygeal approach. <i>Urology</i> , 1997, 49, 392-399.	0.5	0
184	RE: NERVE AND SEMINAL SPARING RADICAL CYSTECTOMY WITH ORTHOTOPIC URINARY DIVERSION FOR SELECT PATIENTS WITH SUPERFICIAL BLADDER CANCER: AN INNOVATIVE SURGICAL APPROACH. <i>Journal of Urology</i> , 2001, 166, 1402-1402.	0.2	0
185	Re: Sexuality Preserving Cystectomy And Neobladder: Initial Results. <i>Journal of Urology</i> , 2002, 167, 1803-1803.	0.2	0
186	In regard to Cozzarini et al.: Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: A single-institute experience of 415 patients (<i>Int J Radiat Oncol Biol</i>) Tj ETQq0 0 0 rBT /Overlock 10 T		
187	Bilateral Renal Mass Suggestive of Cancer. <i>European Urology</i> , 2006, 49, 746-747.	0.9	0
188	Bilateral Renal Mass Suggestive of Cancer: Part 2. <i>European Urology</i> , 2006, 49, 918-920.	0.9	0
189	Editorial Comment on: PO Stage at Radical Cystectomy for Bladder Cancer is Associated with Improved Outcome Independent of Traditional Clinical Risk Factors. <i>European Urology</i> , 2007, 52, 774-775.	0.9	0
190	Editorial Comment on:Comparison of Complications in Three Incontinent Urinary Diversions. <i>European Urology</i> , 2008, 54, 833-834.	0.9	0
191	Editorial Comment on: HYAL-1 Hyaluronidase: A Potential Prognostic Indicator for Progression to Muscle Invasion and Recurrence in Bladder Cancer. <i>European Urology</i> , 2010, 57, 93-94.	0.9	0
192	Reply to Manish Garg, Apul Goel and Jai Prakash's Letter to the Editor re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non-muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study. <i>Eur Urol</i> 2012;62:797-802. <i>European Urology</i> , 2013, 63, e7-e8.	0.9	0
193	When the Conservative Treatment in High-Risk Non-Muscle Invasive Bladder Cancer Patients should be Abandoned. <i>Urologia</i> , 2013, 80, 48-52.	0.3	0
194	Case Discussion: A Man with Two Synchronous and Symptomatic Malignancies Related to Smoking: The Case for Surgery. <i>European Urology Focus</i> , 2015, 1, 92-93.	1.6	0
195	In reply to: Lawless et al. Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progression. <i>Histopathology</i> , 2018, 72, 361-362.	1.6	0
196	Factores de riesgo de enfermedad residual en la re-RTU en una gran cohorte de pacientes con enfermedad T1G3. <i>Actas Urológicas Españolas</i> , 2021, 45, 473-473.	0.3	0
197	Re: Sexuality Preserving Cystectomy And Neobladder: Initial Results. <i>Journal of Urology</i> , 2002, , 1803.	0.2	0
198	Re: Evaluation of Cause of Death after Radical Cystectomy for Patients with Bladder Cancer: The Impact of Age at the Time of Surgery. <i>Journal of Urology</i> , 2019, 202, 1076-1077.	0.2	0

#	ARTICLE	IF	CITATIONS
199	Multicentre International Study for the Prevention with laluriÂ® of Radio-Induced Cystitis (MISTIC): A Randomised Controlled Study. SSRN Electronic Journal, 0, , .	0.4	0